Fox Run Management L.L.C. Makes New Investment in Hologic, Inc. $HOLX

Fox Run Management L.L.C. acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 3,774 shares of the medical equipment provider’s stock, valued at approximately $246,000.

A number of other institutional investors have also recently made changes to their positions in HOLX. Chung Wu Investment Group LLC acquired a new position in Hologic during the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 273 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of Hologic in the 1st quarter valued at approximately $34,000. Cromwell Holdings LLC boosted its stake in Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 436 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Hologic in the 1st quarter worth approximately $42,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Buying and Selling

In other news, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.88% of the company’s stock.

Hologic Price Performance

NASDAQ:HOLX opened at $74.26 on Friday. The firm’s fifty day moving average is $69.62 and its two-hundred day moving average is $65.57. The firm has a market cap of $16.52 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 2.54 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic, Inc. has a one year low of $51.90 and a one year high of $80.31.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the business posted $1.01 EPS. The company’s revenue was up 6.2% on a year-over-year basis. Research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on HOLX. Mizuho lowered shares of Hologic from an “outperform” rating to a “neutral” rating and upped their price target for the company from $70.00 to $78.00 in a research note on Thursday, October 23rd. Morgan Stanley upped their target price on Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research report on Tuesday. BTIG Research restated a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. UBS Group boosted their price target on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday, July 31st. Finally, Raymond James Financial lowered Hologic from a “moderate buy” rating to a “hold” rating in a report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $79.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.